Sunday 16 December 2018
Home      All news      Contact us     
Stony Brook - 4 month ago

First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. T

Related news

Latest News
Hashtags:   

First

 | 

Human

 | 

Clinical

 | 

Trial

 | 

Targeting

 | 

Protein

 | 

Aggressive

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources